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Abstract
Characteristic cytokine patterns have been described in different cancer patients and they
are related to their diagnosis, prognosis, prediction of treatment responses and survival. A
panel of cytokines was evaluated in the plasma of non-small cell lung cancer (NSCLC)
patients and healthy controls to investigate their profile and relationship with clinical charac-
teristics and overall survival. The case-controlled cross-sectional study design recruited 77
patients with confirmed diagnosis of NSCLC (cases) and 91 healthy subjects (controls)
aimed to examine peripheral pro-inflammatory and anti-inflammatory cytokines (IL-2, IL-4,
IL-6, IL-10, IL-17A, TNF and IFN-γ) by Cytometry Beads Arrays (CBA Flex) in. The cytokine
IL-6 showed a statistically significant difference among groups with increased expression in
the case group (p < 0.001). The correlation between the cytokines expression with patient’s
clinical characteristics variables revealed the cytokine IL-6 was found to be associated with
gender, showing higher levels in male (p = 0.036), whereas IL-17A levels were associated
with TNM stage, being higher in III–IV stages (p = 0.044). We observed worse overall sur-
vival for individuals with high levels of IL-6 when compared to those with low levels of this
cytokine in 6, 12 and 24 months. Further studies of IL-6 levels in independent cohort could
clarify the real role of IL-6 as an independent marker of prognostic of NSCLC.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide [1]. Histologically, lung
cancer is divided into two main types: small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC) [2]. Approximately 80–85% of all cases are diagnosed as NSCLC and about
70% of patients have locally advanced or metastatic disease at the time of diagnosis [3–5]. The
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overall 5-year survival rate is only 14–17% [6], due mainly, to the poor detection of lung cancer
in its early stages and the ineffective treatment for advanced stages [7].
Intense inflammation is reported in NSCLC and it is significantly associated with disease
progression and decreased survival of patients [8]. The inflammation caused by immune system
activation is likely linked to carcinogenesis by promoting angiogenesis and proliferation of
tumour cells [9,10], according to the cytokine profile in the tumour microenvironment [11–14].
Cytokines are a diverse group of small and soluble polypeptides and glycoproteins pro-
duced by various cell types, mainly by immune cells but also cancer cells, comprising interleu-
kins (IL), interferon (IFN), chemokines, tumour necrosis factor (TNF) and growth factors
[15]. Cytokines can act locally or systemically in different cell types, triggering signalling path-
ways responsible for cell activation, proliferation, growth, differentiation, migration and cyto-
toxicity [16,17]. In carcinogenesis cytokines have dual effects they can be involved in the
activation of immune effector mechanisms, that limit the tumour growth, or in malignant
transformation, tumour growth, invasion and metastasis [11]. Characteristic cytokine patterns
have been described in different cancer patients and they are related to their diagnosis, prog-
nosis, prediction of treatment responses [18] and survival [7].
In this study a panel of seven cytokines, frequently associated to lung cancer development,
was evaluated in the plasma of patients with NSCLC and healthy controls to investigate their
profile and its relationship with clinical characteristics and overall survival.
Materials and methods
Patients and healthy volunteers
This was a prospective, cross-sectional study, in which patients were recruited consecutively from
the Chest Department of Barretos Cancer Hospital (Barretos, Brazil) from January 2013 to Octo-
ber 2015. For the purpose of this research, 77 patients with NSCLC confirmed by histological
examinations of samples obtained during fiberoptic broncoscopy were recruited consecutively
before any treatment or primary lung surgery. Pathologic stages were determined according to
the criteria of World Health Organization [19]. Healthy volunteers (controls) (n = 91) were
recruited from blood donors who were received at the same hospital from January to October
2015 with excellent health status at the moment of the study. The written informed consent was
obtained from each volunteer upon approval of the study by Barretos Cancer Hospital Ethic
Committee (number 889/ 2014) and all subjects answered a questionnaire containing socio-
demographic and life style characteristics (S1 File), and authorized the use of tissue samples and
clinical data for research. The median ages were 59.8 years (age range: 43–76 years) and 57.1
years (age range: 34–69 years) of the patients and the healthy volunteers, respectively.
Blood samples
Peripheral venous blood samples (4mL) were collected in EDTA tube (BD Vacutainer, BD Bio-
sciences, USA) from both patients and controls groups at one time point and subsequently
centrifuged at 2125 g for 10 minutes at 4˚C and the supernatant (plasma) frozen into micro-
tubes at -80˚C until to be used. From patients, blood was collected at pre-treatment time, more
specifically prior to bronchoscopy and, from healthy individuals, blood was obtained before
blood donation.
Cytokines analysis
Plasma levels of the cytokines IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ and IL-17A (human Th1/
Th2/Th17 CBA kit; BD Biosciences, San Jose, CA, USA) were measured by cytometric bead
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assay (CBA) according to the manufacturer’s protocol. However, reaction volume was reduced
to 25 μl/ sample as previously demonstrated [20]. Briefly, seven capture bead populations with
distinct fluorescence intensities and coated with cytokine-specific capture antibodies were
mixed together in equal volumes: 25 μL of each sample and 25 μL of PE-conjugated detection
antibodies were added to 25 μL of mixed-bead populations. The mixture was incubated for 3
hours at room temperature in the dark to form sandwich complexes. The beads were then
washed with wash buffer, and data acquired with a BD FACSCanto™ platform (BD Biosciences,
San Jose, CA, USA). FACSDiva and FCAP Array™ software (BD Biosciences) were used for the
analyses.
Statistical analysis
The participants’ age was calculated for both groups through the T-Student test. The compari-
sons between socio-demographic and life style parameters were analysed using χ2 test or Fish-
er’s exact test, when indicated. The comparisons between clinical parameters and cytokines
levels were analysed using T-Student test or Mann-Whitney U test. And the comparisons of
cytokines levels between groups were described by mean, standard deviation, median, mini-
mum and maximum using Mann-Whitney U Test.
The Receiver Operating Characteristic (ROC) curve was used to establish the cut-off val-
ues for the cytokines according to the event of patient’s status (died/ alive). Comparisons
between the groups were analysed by χ2 test. The survival rate was estimated by Kaplan-
Meier method and the evaluation of association between IL-6 level and survival time was
estimated by log-rank test. Multivariate analyses using an adjust Cox proportional hazards
model were used to identify significant independent variables. Were considered statistically
significant p value <0.05.
All statistical analyses were performed with IBM SPSS Statistics software 21.0 (SPSS, Chi-
cago, USA).
Results
Patients and healthy volunteers characteristics
Seventy-seven lung cancer (LC) patients and 91 control individuals were included in the study.
Among patients, 45 had squamous cell carcinoma and 32 adenocarcinoma. Further, 90.5%
were in TNM stage III–IV and 51.7% of tumors presented as a mass poorly differentiated.
Both patients and controls were not different regarding to gender and race, nonetheless in LC
patients a strong association with history of cigarette smoking is shown (p< 0.001) as well as
in passive smoke exposed individuals (p< 0.001) (Table 1). To clarify, we consider active
smokers those smoking at the time of interview or stopped in the last 12 months, and non-
smokers those who never smoked or who stopped for more than 12 months. As passive smok-
ers were considered those individuals who lived with active smokers at the time of interview
and / or in the past with active smokers in the home environment and / or in the workplace.
Cytokine detection
CBA was carried out to assess the cytokine expression levels; basically classified as pro-inflam-
matory IL-2, IL-6, IFN-γ, TNF and IL-17A and, anti-inflammatory such as IL-4 and IL-10.
Among the pro-inflammatory cytokines, IL-6 was the only one showing statistically significant
difference between the groups (p< 0,001) with higher value in the patients (Table 2). No sig-
nificant difference was found among the anti-inflammatory cytokines (Table 2).
IL-6 in non-small cell lung cancer
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Table 1. Baseline characteristics of NSCLC patients and healthy subjects.
Variable NSCLC patients Healthy subjects P
n (%) n (%)
Gender
Female 21 (27.3) 27 (29.7) 0.732
Male 56 (72.7) 64 (70.3)
Race
White 61 (80.3) 68 (74.7) 0.395
No white 15 (19.7) 23 (25.3)
Smoking history
No 35 (45.5) 76 (83.5) <0.001
Yes 42 (54.5) 15 (16.5)
Passive smoke
No 27 (35.1) 64 (70.3) <0.001
Yes 50 (64.9) 27 (29.7)
Histology
Squamous cell carcinoma 45 (58.4) -
Adenocarcinoma 32 (41.6) -
TNM stage
I—II 7 (9.5) -
III—IV 67 (90.5) -
Degree of differentiation
Well/ moderated 29 (48.3) -
Poorly 31 (51.7) -
Total 77 91
NSCLC: non-small cell lung cancer; TNM stage: System based on the size and / or extent of the primary tumor (T), amount of compromised lymph nodes
(N) and presence of metastases (M).
https://doi.org/10.1371/journal.pone.0181125.t001
Table 2. Cytokine expression levels between NSCLC patients and healthy subjects.
Cytokines
Groups










IL-2 2.48 (2.14) 2.07 (0–8.10) 3.06 (2.73) 2.67 (0–18.73) 0.157
IL-6 25.03 (36.40) 15.16 (0.66–231.0) 2.21 (1.30) 1.90 (0.36–7.70) <0.001
IFN-γ 2.22 (7.75) 0.86 (0–68.01) 1.27 (1.45) 0.47 (0–5.72) 0.884
TNF 0.86 (0.98) 0.59 (0–4.47) 1.03 (1.98) 0.72 (0–15.17) 0.843
IL-17 A 12.76 (9.74) 10.56 (0–62.73) 12 (6.29) 10.26 (0–29.67) 0.726
Anti-inflammatory
IL-4 0.92 (1.03) 0.67 (0–5.14) 1.02 (1.37) 0.89 (0–10.14) 0.692
IL-10 1.19 (1.56) 0.76 (0–9.39) 0.76 (1.05) 0.66 (0–9.84) 0.074
Total 77 91
NSCLC: non-small cell lung cancer; SD: standard deviation; pg/mL: picogram/milliliter; IL: interleukin; IFN: interferon; TNF: tumor necrosis factor.
https://doi.org/10.1371/journal.pone.0181125.t002
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Correlation between cytokine levels, socio-demographic and lifestyle
characteristics and clinical data
The correlation between the cytokines expression with patient‘s clinic-pathologic variables
revealed that among all cytokines evaluated, only IL-6 and IL-17A showed statistical significant
difference with socio-demographic characteristic and clinical data, respectively. Median con-
centration of IL-6 was statistically associated with gender, showing to be higher in male (16.67
pg/mL, range 1.44 pg/mL–34.66 pg/mL) than in female (10.06 pg/mL, range 1.44 pg/mL–
34.66 pg/mL) (p = 0.036). And, median concentration of IL-17A was associated with TNM
stage, being higher levels in III-IV stage (11.82 pg/mL, range 0 pg/mL– 62.7 pg/mL) than in
I-II stage (8.75 pg/mL, range 0 pg/mL– 11.8 pg/mL) (p = 0.044) (data not shown in table).
Correlation between cytokine levels and survival
We also evaluated the association among study variables, plasma levels of cytokines and sur-
vival of NSCLC patients. However, among the variables we analyzed, only IL-6, TNM stage
and degree of differentiation had a significant influence on survival rates through the analysis
of Kaplan-Meier and log-rank. The time for overall survival (OS) was calculated over the inter-
val of the dates of diagnosis and death or the date of the last information. For IL-6, the cut-off
point was 8.05 pg/ml, sensitivity of 86.8% and specificity of 43.6%. Accordingly, the patients
were divided into high and low plasma levels, corresponding to 55 (71.4%) and 22 (28.6%)
individuals, respectively.
Table 3 shows that the OS estimated at 6 months was 95.5%, at 12 months was 56.3% and at
24 months was 32.2%. As for IL-6, we observed that those patients showing high IL-6 plasma
level showed a significantly worse OS (p = 0.001) as compared to individuals with low IL-6
plasma levels. Considering the clinical data, we observed that patients with I–II staging had
better OS at 6, 12 and 24 months, estimated at 86.4%, while those with III–IV staging pre-
sented OS estimated at 95.7% in 6 months, 54.8% in 12 months and 25.7% in 24 months
(p = 0.029). For the degree of differentiation (well/ moderated and poorly), we observed a
worse OS rate for patients with a poor differentiation degree when compared those with well/
moderated differentiation degree (p = 0.026). Results of Kaplan-Meier survival analyses and
log-rank tests are shown below (Figs 1–4).
Additionally, the multivariate Cox regression analysis revealed that only IL-6 levels was inde-
pendent prognostic factors for predicting poorer OS in NSCLC patients (Hazard ratio = 5.81,
95% CI = 1.74–19.33, p = 0.004).
Table 3. Estimate of overall survival considering the clinical variables and plasma level of IL-6.
Variable Categories N˚ Cases N˚ Deaths Probability of survival (%) P
6 months 12 months 24 months
Overall survival - 79 40 95.0 56.3 32.2 -
IL-6 Low 22 5 86.4 86.4 68.0 0.001
High 55 33 52.4 41.3 18.6
TNM stage I—II 7 1 85.7 85.7 85.7 0.029
III—IV 69 37 95.7 54.8 25.7
Degree of differentiation Well/ moderated 31 14 78.4 71.0 41.4 0.026
Poorly 31 21 48.4 39.6 22.6
IL: interleukin; TNM stage: system based on the size and / or extent of the primary tumor (T), amount of compromised lymph nodes (N) and presence of
metastases (M).
https://doi.org/10.1371/journal.pone.0181125.t003
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Discussion
The immune system of the lung can be represented by cells and cytokines which have different
functions; under physiological conditions, the dynamics of these elements is stable and the
Fig 1. Kaplan-Meier overall survival of NSCLC patients.
https://doi.org/10.1371/journal.pone.0181125.g001
Fig 2. Kaplan-Meier survival estimates by stratification of serum IL-6 concentration in NSCLC
patients.
https://doi.org/10.1371/journal.pone.0181125.g002
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ratio of immune cells and molecules (eg, cytokines) is maintained within normal limits, as a
result there is no generation of harmful responses to the host. Specific unbalances in these
physiologic immune responses, as those caused by lung cancer can serve as biomarkers and
Fig 4. Kaplan-Meier survival estimates by stratification of degree of differentiation in NSCLC patients.
https://doi.org/10.1371/journal.pone.0181125.g004
Fig 3. Kaplan-Meier survival estimates by stratification of TNM stage in NSCLC patients.
https://doi.org/10.1371/journal.pone.0181125.g003
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predictive factors in relation to immunotherapy [21]. Also a better understanding of the
dynamics of these cells and molecules in pathologic conditions may unravel, promising strate-
gies for the treatment of neoplasias.
Inflammatory responses play a dual role in tumor development. In some situations, they
support the inhibition of tumor growth by promoting the antitumor activity of cytotoxic T
cells [22], which could limit the proliferation of transformed cells (or tumor growth) and
induce even elimination. On the other hand, the induction of DNA damage by free radical
production in chronic inflammation [22] can contribute to create a favorable environment to
tumor progression [23]. Since inflammation can be also triggered by a variety of pathogens
and environmental factors [24] and once lung is vulnerable to various pathogens and gaseous
pollutants the persistent exposure to these factors can trigger the production of cytokines that
result a chronic inflammatory environment capable to induce cell transformation and subse-
quent tumor growth [24,25].
Various biological processes such as proliferation, differentiation, migration, activation,
and cell growth are coordinated by cytokines, as well as the tumor development [15,26,27].
Cytokines may contribute to tumor development in, at least, two ways: stimulating cell growth
and differentiation and inhibiting apoptosis of abnormal cells [9]. Some studies have shown
that cytokines measured in several biological fluids, such as plasma, can reflect various dis-
eases, including cancer [28].
When analyzed the plasma levels of cytokines between the groups we studied, only the pro-
inflammatory cytokine IL-6 showed statistically significant value with increased expression in
group of patients with NSCLC, and strong association with disease development. Among the
functions already mentioned as being related to IL-6, stand out those involved with differentia-
tion of T and B cells, stimulation of hematopoiesis [29] and inducing of phosphorylation of
STAT3 and STAT1 transcription factors [30]. Also, IL-6 was demonstrated to be activated in
many human cancers, including lung cancer [31]. In this situation, IL-6 acts directly in the
prevention of apoptosis by deleting the genes involved in cell cycle and acts as an autocrine
growth factor for tumors [30]. It is considered as a major pro-inflammatory cytokines related
to tumor progression in NSCLC [24].
Regarding the clinical data, our study showed a correlation of peripheral level of IL-6 with
only survival. However, the relationship between the high cytokine level in males was similar
to those found in the literature [32]. In relation to lifestyle data, IL-6 showed high expression
in smokers in both study groups, both active and passive smokers. The smoking is associated
with systemic inflammation and, it is suggested that IL-6 may have a role in the inflammatory
response associated with smoking [32]. When the relationship between IL-6 and active and
passive smoking was analyzed only for the NSCLC group, there was no significant correlation.
This suggests that the high IL-6 expression levels in NSCLC individuals are related to disease
and not to smoking.
We found that IL-17A was the only cytokine evaluated that significantly correlated with
advanced stages of the disease. IL-17A effects on growth and metastasis of lung cancer cells has
also been explored in animal models of development of disease [33]. After measuring the size
of tumor mass, the amount of cytokine at the site and density of infiltrating macrophages in
cancer mass, it was observed that animals that received IL-17 exogenously exhibited greater
tumor size, increased number of infiltrating macrophages in mass, greater amount of vascular
endothelial cells, increased expression of VEGF (vascular endothelial growth factor), metallo-
proteinases 9 and 2, and TNF, as compared to the control group that received saline [33].
The role of IL-17A has also been investigated in other tumor types such as colorectal,
esophageal squamous cells carcinoma, ovary and hepatocellular carcinoma. The presence of
IL-17A in colorectal cancer, hepatocellular carcinoma and NSCLC is generally associated with
IL-6 in non-small cell lung cancer
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poor prognosis, whilst the presence of IL-17A in ovarian carcinoma and esophageal squamous
cells carcinoma is associated with anti-tumor response [34,35]. In general, the cytokine IL-17A
produced by Th17 cells, has dual role in antitumor immunity. In one hand IL-17 can exert
anti-angiogenic and apoptotic activities, on the other hand it can promote the activity of cyto-
toxic T cells effectors [36,37].
We also found a significant association among individuals classified as high plasma levels of
IL-6 and worst probability of survival at 6, 12 and 24 months. In this line, the study of Chang
et al. with 245 NSCLC patients with advanced stage of the disease, showed that high levels of
IL-6 was associated with poorer response to treatment and survival in patients undergoing
chemotherapy [7]. The relationship of this worst therapeutic response with deregulated
expression of certain cytokines favoring resistance to treatment has been strongly suggested by
other authors [38]. Despite our minute understanding of the mechanisms of resistance exerted
by cytokines, it is nowadays clear that they represent potential biomarkers and therapeutic tar-
gets in cancer, requiring therefore more investigations [29].
Other studies analyzed the IL-6 expression in tumor tissue, plasma and bronchoalveolar
lavage, and found a correlation with progression, resistance to anti-tumor therapies and poor
survival of patients with lung cancer [7,39,40]. The association between high levels of IL-6 and
lower survival was also observed in patients with renal cell carcinoma [41], chronic lympho-
cytic leukemia [42], gastric carcinoma [43], prostate cancer [44], gastrointestinal cancer [45]
and breast cancer [46].
The high IL-6 levels detected in the circulation by us and others suggest that these cytokine
may be a marker of worse prognosis for patients with advanced NSCLC or for those treated
with chemotherapy [7]. Although 40% of patients with NSCLC express high concentration of
IL-6, the mechanisms responsible for this correlation between IL-6 expression and poor prog-
nosis remains to be clarified [39]. Clinical and epidemiological studies suggest a strong associa-
tion between chronic inflammation and some types of cancer, including NSCLC. The increased
plasma levels of cytokines can act as an independent marker of survival in patients with lung
cancer. Despite the lack of understanding of the relationship of cytokines with the mechanisms
of tumor progression and survival, we can not exclude that cytokines are potential circulating
biomarkers, to characterize subgroups of patients and provide relevant information to new tar-
get therapies [7], with the advantage that they are easily measured and simple to obtain. Despite
this, a limitation of our study is that we did not evaluate the source of Il-6 detecada nor the cell
responsible for its production.
In conclusion, individuals with NSCLC exhibit high levels of IL-6 with significantly worse
survival, suggesting that this cytokine may act as an independent marker of prognostic for
overall survival of these patients.
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